Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia

被引：0

作者：

Mashima, Kiyomi ^{[1
]}

Ikeda, Takashi ^{[1
]}

Kawaguchi, Shin-ichiro ^{[1
]}

Toda, Yumiko ^{[1
]}

Ito, Shoko ^{[1
]}

Ochi, Shin-ichi ^{[1
]}

Nagayama, Takashi ^{[1
]}

Umino, Kento ^{[1
]}

Minakata, Daisuke ^{[1
]}

Nakano, Hirofumi ^{[1
]}

Yamasaki, Ryoko ^{[1
]}

Morita, Kaoru ^{[1
]}

Kawasaki, Yasufumi ^{[1
]}

Sugimoto, Miyuki ^{[1
]}

Ishihara, Yuko ^{[1
]}

Ashizawa, Masahiro ^{[1
]}

Yamamoto, Chihiro ^{[1
]}

Fujiwara, Shin-ichiro ^{[1
]}

Hatano, Kaoru ^{[1
]}

Sato, Kazuya ^{[1
]}

Oh, Iekuni ^{[1
]}

Ohmine, Ken ^{[1
]}

Muroi, Kazuo ^{[1
]}

Kanda, Yoshinobu ^{[1
]}

机构：

[1] Jichi Med Univ, Dept Med, Div Hematol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan

来源：

ANNALS OF HEMATOLOGY | 2019年 / 98卷 / 05期

关键词：

Myelodysplastic syndromes (MDS); Erythroid hyperplasia; Non-erythroid cells (NEC); Acute myeloid leukemia (AML); PROGNOSTIC SCORING SYSTEM; CELLULARITY IMPROVES;

D O I：

10.1007/s00277-018-3560-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is controversial whether blast percentage based on all nucleated cells (ANC) or non-erythroid cells (NEC) more accurately reflects the prognosis of patients with myelodysplastic syndromes (MDS). We considered that the impact of blast percentage on survival should be similar in MDS with erythroid hyperplasia (MDS-E) and MDS with no erythroid hyperplasia (MDS-NE), and from this perspective, we retrospectively analyzed 322 patients, including 44 with MDS-E and 278 with MDS-NE. Overall survival was similar between the MDS-E and MDS-NE groups (P = 0.94). In a subgroup of patients with bone marrow (BM) blasts of <5%, no difference in survival was found between MDS-E and MDS-NE by either calculation method. However, in patients with a blast percentage between 5 and 10%, a significant difference in survival was observed only when the blast percentage in MDS-E was calculated from ANC (P < 0.001 by ANC and P = 0.66 by NEC). A similar result was observed when we analyzed the remaining patients with higher blasts together with those with blasts between 5 and 10%. These results suggest that the calculation of the BM blast percentage based on NEC in MDS-E provides a blast percentage value with a clinical impact consistent with that in MDS-NE.

引用

页码：1127 / 1133

页数：7

共 45 条

[31] Multiple DNA fragmentation patterns in spontaneous apoptotic death of bone marrow cells and enhancement of all in myelodysplastic syndromes (MDS).
Mundle, S
Cartlidge, J
Venugopal, P
Gezer, S
Hines, C
Gregory, SA
Alvi, S
Shetty, V
Borok, R
Showel, M
Hussaini, S
Dar, S
Robin, EL
Rifkin, SD
Alston, D
Hernandez, BM
Shah, R
Raza, R
BLOOD, 1996, 88 (10) : 3558 - 3558
[32] RECOMBINANT HUMAN ERYTHROPOIETIN AND DARBEPOIETIN ALPHA EXERTS DIFFERENTIAL EFFECTS ON NON- ERYTHROID HAEMOPOIETIC CELLS AND BONE MARROW MICROENVIRONMENT
Dewamitta, Sita
Lim, Hui
Singbrant, Sofie
Russell, Megan
Mullally, Ann
Ebert, Benjamin
Nandurkar, Harshal
Walkey, Carl
EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : S97 - S98
[33] Enrichment of donor erythroid cells after non-myeloablative bone marrow transplantation (BMT) for sickle cell anemia (SCA).
Walters, MC
Woolfrey, A
Torok-Storb, B
Zaucha, JM
Little, MT
Trachtenberg, E
Sullivan, KM
Storb, R
BLOOD, 2001, 98 (11) : 490A - 490A
[34] The new WHO classification (2016) defines a revised diagnostic approach to myeloid neoplasms with erythroid precursors comprising ≥ 50% of bone marrow nucleated cells: Applicability and clinical impact
Haferlach, T.
Kern, W.
Perglerova, K.
Haferlach, C.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 109 - 109
[35] Comparison of differential gene expression in unselected bone marrow and purified CD34+-cells from patients with myelodysplastic syndromes
Neumann, M.
Nolte, F.
Benlasfer, O.
Nowak, V
Schumann, C.
Baldus, C. D.
Thiel, E.
Hofmann, W-K
ONKOLOGIE, 2010, 33 : 223 - 223
[36] Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders
Cortelezzi, Agostino
Colombo, Gualtiero
Pellegrini, Caterina
Silvestris, Ilaria
Mazzeo, Lorenza Moronetti
Bosari, Silvano
Deliliers, Giorgio Lambertenghi
Fracchiolla, Nicola Stefano
AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) : 531 - 539
[37] Porcine reproductive and respiratory syndrome type 1 viruses induce hypoplasia of erythroid cells and myeloid cell hyperplasia in the bone marrow of experimentally infected piglets independently of the viral load and virulence
Paola Amarilla, Shyrley
Gomez-Laguna, Jaime
Carrasco, Librado
Rodriguez-Gomez, Irene M.
Caridad y Ocerin, Jose M.
Graham, Simon P.
Frossard, Jean-Pierre
Steinbach, Falko
Salguero, Francisco J.
VETERINARY MICROBIOLOGY, 2017, 201 : 126 - 135
[38] EFFECT OF THE NON-PEPTIDE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (PROMACTA®/REVOLADETM) ON BONE MARROW CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
Will, B.
Luciano, J. P.
Kawahara, M.
Erickson-Miller, C.
Verma, A.
Aivado, M.
Steidl, U.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 71 - 71
[39] Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes
Mossner, Maximilian
Wilbertz, Axel
Fey, Stephanie
Oblaender, Julia
Nowak, Verena
Vogler, Jovita
Nolte, Florian
Bieber, Ralf
Hofmann, Wolf-Karsten
Reinwald, Mark
Nowak, Daniel
BLOOD, 2013, 122 (21)
[40] Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: A comparison between FACS analysis and immunohistochemistry
KanterLewensohn, L
HellstromLindberg, E
Kock, Y
ElmhornRosenborg, A
Ost, A
EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 56 (03) : 124 - 129

← 1 2 3 4 5 →